Keyword: Faslodex

5. Ibrance

Ibrance—the first in a new class of CDK 4/6 inhibitors—has romped away since Pfizer launched it in the U.S. in February 2015 as a combination therapy with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that has spread to another part of the body.